title: Evaluation of survivin splice variants in pituitary tumors.
abstract: OBJECTIVE
  Survivin is an apoptosis inhibitor, expressed in almost all types of human malignancies, but rarely in differentiated normal tissues. Recently, survivin gene splice variants with different anti-apoptotic activities have been reported. The current study was undertaken to examine the expression of survivin and its splice variants ∆Ex3 and 2β in pituitary tumors, and to correlate the amount of particular transcripts with clinical staging in pituitary adenomas. Quantitative detection of survivin and its splice variants ∆Ex3 and 2β transcripts in non-cancerous pituitary tissues (n = 12) and different types of pituitary tumor (n = 50).
  
  
  METHODS
  Samples were collected from 50 pituitary tumors including 26 non-functional tumors, 21 GH-secreting tumors, 2 PRL-secreting tumors and 1 ACTH-secreting tumor. 12 normal pituitary glands received after autopsy served as a control of the study. 29 thyroid cancers tissues were used as a positive control. The RT-qPCR with TaqMan hydrolysis probes were used to determine the expression of analyzed splice variants of survivin.
  
  
  RESULTS
  The obtained data showed that both survivin and its splice variants were expressed in different types of pituitary adenoma as well as in normal pituitary tissue. However, the level of its expression was similar in all studied cases. Patient age negatively correlated with tumor invasiveness. Moreover, our study showed a tendency for negative correlation between patient age and tumor diameter.
  
  
  CONCLUSIONS
  No significant differences between survivin and its splice variants ∆Ex3 and 2β expression in pituitary tumors and in normal pituitary glands as well as in invasive and in non-invasive tumors were found, suggesting that survivin does not play a significant role in pituitary tumorigenesis.
authors.affiliation: Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Przybyszewski Street 49, 60-355, Poznań, Poland, joanna.stachura@gmail.com.
authors.forename: Joanna
authors.initials: J
authors.lastname: Waligórska-Stachura
authors.forename: Mirosław
authors.initials: M
authors.lastname: Andrusiewicz
authors.forename: Nadia
authors.initials: N
authors.lastname: Sawicka-Gutaj
authors.forename: Marta
authors.initials: M
authors.lastname: Kubiczak
authors.forename: Anna
authors.initials: A
authors.lastname: Jankowska
authors.forename: Włodzimierz
authors.initials: W
authors.lastname: Liebert
authors.forename: Agata
authors.initials: A
authors.lastname: Czarnywojtek
authors.forename: Ryszard
authors.initials: R
authors.lastname: Waśko
authors.forename: Al Ricardo
authors.initials: AR
authors.lastname: Blanco-Gangoo
authors.forename: Marek
authors.initials: M
authors.lastname: Ruchała
mesh_terms: D049913:ACTH-Secreting Pituitary Adenoma / Q000235:genetics* / Q000473:pathology; D000236:Adenoma / Q000235:genetics* / Q000473:pathology; D000328:Adult; D000367:Age Factors; D000368:Aged; D017398:Alternative Splicing; D016022:Case-Control Studies; D005260:Female; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000235:genetics* / Q000473:pathology; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010911:Pituitary Neoplasms / Q000235:genetics* / Q000473:pathology; D015175:Prolactinoma / Q000235:genetics* / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077022:Survivin; D047368:Tumor Burden
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D012333:RNA, Messenger; D000077022:Survivin
references.citation: Cancer Res. 1998 Dec 1;58(23):5315-20
references.pmid: 9850056
references.citation: Anticancer Res. 2002 Mar-Apr;22(2A):805-8
references.pmid: 12014654
references.citation: Biochem Biophys Res Commun. 2003 May 30;305(2):374-9
references.pmid: 12745085
references.citation: Br J Cancer. 2002 Mar 4;86(5):737-43
references.pmid: 11875736
references.citation: Hum Pathol. 2003 Nov;34(11):1119-26
references.pmid: 14652813
references.citation: Appl Immunohistochem Mol Morphol. 2004 Dec;12(4):296-304
references.pmid: 15536328
references.citation: Drug Resist Updat. 2002 Apr;5(2):65-72
references.pmid: 12135582
references.citation: Front Neuroendocrinol. 2000 Jul;21(3):174-98
references.pmid: 10882539
references.citation: J Clin Endocrinol Metab. 1999 Feb;84(2):761-7
references.pmid: 10022450
references.citation: Best Pract Res Clin Endocrinol Metab. 2010 Jun;24(3):461-76
references.pmid: 20833337
references.citation: Cancer Res. 1999 Dec 15;59(24):6097-102
references.pmid: 10626797
references.citation: J Clin Invest. 2003 Dec;112(11):1603-18
references.pmid: 14660734
references.citation: Neuro Endocrinol Lett. 2009;30(4):477-81
references.pmid: 20010504
references.citation: N Engl J Med. 1999 Aug 5;341(6):452-3
references.pmid: 10438269
references.citation: J Clin Endocrinol Metab. 1995 May;80(5):1733-8
references.pmid: 7745027
references.citation: Ginekol Pol. 2012 Jul;83(7):537-40
references.pmid: 22880480
references.citation: Clin Cancer Res. 2000 Jan;6(1):127-34
references.pmid: 10656440
references.citation: Clin Cancer Res. 2008 Aug 15;14(16):5000-5
references.pmid: 18698017
references.citation: Saudi Med J. 2008 Nov;29(11):1589-92
references.pmid: 18998006
references.citation: Br Med Bull. 2006 May 09;75-76:81-97
references.pmid: 16684928
references.citation: Reproduction. 2001 Mar;121(3):363-71
references.pmid: 11226062
references.citation: BMC Cancer. 2014 Mar 12;14:176
references.pmid: 24620748
references.citation: Mol Cancer. 2005 Mar 02;4(1):11
references.pmid: 15743529
references.citation: Mol Cancer Ther. 2006 May;5(5):1087-98
references.pmid: 16731740
references.citation: PLoS One. 2014 Jun 19;9(6):e100534
references.pmid: 24945990
references.citation: Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4349-54
references.pmid: 11917134
references.citation: World J Gastroenterol. 2004 Nov 15;10(22):3245-50
references.pmid: 15484293
references.citation: Br J Cancer. 2008 Mar 25;98(6):1109-17
references.pmid: 18283319
references.citation: Endocr Pathol. 2012 Jun;23(2):123-31
references.pmid: 22327960
references.citation: Neuro Endocrinol Lett. 2008 Dec;29(6):1033-7
references.pmid: 19112393
references.citation: J Neurosurg. 2003 Oct;99(4):738-45
references.pmid: 14567610
references.citation: Cancer. 2006 Mar 1;106(5):1123-9
references.pmid: 16456815
references.citation: Br J Cancer. 2005 Jan 31;92(2):212-6
references.pmid: 15611788
references.citation: Biochem Biophys Res Commun. 2002 Sep 13;297(1):59-64
references.pmid: 12220508